My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 178

    1.

    A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.

    Edelman S, Garg S, Frias J, Maggs D, Wang Y, Zhang B, Strobel S, Lutz K, Kolterman O.

    Diabetes Care. 2006 Oct;29(10):2189-95.PMID: 17003291 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.

    Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG.

    Diabetes Care. 2003 Mar;26(3):784-90.PMID: 12610038 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.

    Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolterman OG.

    Diabet Med. 2004 Nov;21(11):1204-12.PMID: 15498087 [PubMed - indexed for MEDLINE]Related articles

    4.

    Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight.

    Karl D, Philis-Tsimikas A, Darsow T, Lorenzi G, Kellmeyer T, Lutz K, Wang Y, Frias JP.

    Diabetes Technol Ther. 2007 Apr;9(2):191-9.PMID: 17425446 [PubMed - indexed for MEDLINE]Related articles

    5.

    Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes.

    Ratner RE, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, Weyer C, Kolterman OG.

    Diabetes Technol Ther. 2002;4(1):51-61.PMID: 12017421 [PubMed - indexed for MEDLINE]Related articles

    6.

    A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.

    Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG.

    Diabetes Care. 2002 Apr;25(4):724-30.PMID: 11919132 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.

    Riddle M, Frias J, Zhang B, Maier H, Brown C, Lutz K, Kolterman O.

    Diabetes Care. 2007 Nov;30(11):2794-9. Epub 2007 Aug 13.PMID: 17698615 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.

    Singh-Franco D, Robles G, Gazze D.

    Clin Ther. 2007 Apr;29(4):535-62. Review.PMID: 17617279 [PubMed - indexed for MEDLINE]Related articles

    9.

    Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.

    Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, Wang Y, Ruggles JA, Kolterman OG, Maggs DG.

    Diabetes Care. 2003 Nov;26(11):3074-9.PMID: 14578242 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes.

    Wysham C, Lush C, Zhang B, Maier H, Wilhelm K.

    Curr Med Res Opin. 2008 Jan;24(1):79-85.PMID: 18031595 [PubMed - indexed for MEDLINE]Related articles

    11.

    Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis.

    Maggs D, Shen L, Strobel S, Brown D, Kolterman O, Weyer C.

    Metabolism. 2003 Dec;52(12):1638-42.PMID: 14669170 [PubMed - indexed for MEDLINE]Related articles

    12.

    Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients.

    Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman OG, Weyer C.

    Obes Res. 2004 Apr;12(4):661-8.PMID: 15090634 [PubMed - indexed for MEDLINE]Related articles

    13.

    Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study.

    Aronne L, Fujioka K, Aroda V, Chen K, Halseth A, Kesty NC, Burns C, Lush CW, Weyer C.

    J Clin Endocrinol Metab. 2007 Aug;92(8):2977-83. Epub 2007 May 15.PMID: 17504894 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets.

    Ratner R, Whitehouse F, Fineman MS, Strobel S, Shen L, Maggs DG, Kolterman OG, Weyer C.

    Exp Clin Endocrinol Diabetes. 2005 Apr;113(4):199-204.PMID: 15891954 [PubMed - indexed for MEDLINE]Related articles

    15.

    Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.

    Levetan C, Want LL, Weyer C, Strobel SA, Crean J, Wang Y, Maggs DG, Kolterman OG, Chandran M, Mudaliar SR, Henry RR.

    Diabetes Care. 2003 Jan;26(1):1-8.PMID: 12502651 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

    Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

    Clin Ther. 2008 Aug;30(8):1448-60. Erratum in: Clin Ther. 2008 Oct;30(10):1937. PMID: 18803987 [PubMed - indexed for MEDLINE]Related articles

    17.

    Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study.

    Chase HP, Lutz K, Pencek R, Zhang B, Porter L.

    J Pediatr. 2009 Sep;155(3):369-73. Epub 2009 May 21.PMID: 19464026 [PubMed - indexed for MEDLINE]Related articles

    18.

    Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes.

    Marrero DG, Crean J, Zhang B, Kellmeyer T, Gloster M, Herrmann K, Rubin R, Fineberg N, Kolterman O.

    Diabetes Care. 2007 Feb;30(2):210-6.PMID: 17259483 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes.

    Riddle M, Pencek R, Charenkavanich S, Lutz K, Wilhelm K, Porter L.

    Diabetes Care. 2009 Sep;32(9):1577-82. Epub 2009 Jun 5.PMID: 19502544 [PubMed - indexed for MEDLINE]Related articles

    20.

    Pramlintide reduces the risks associated with glucose variability in type 1 diabetes.

    Kovatchev BP, Crean J, McCall A.

    Diabetes Technol Ther. 2008 Oct;10(5):391-6.PMID: 18715216 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity